01 / INTEREST
Partners engage, but do not advance.
Positive conversations can mask one unresolved decision issue that keeps an asset outside an internal investment threshold.
Tumor-State Combination Intelligence Platform
Make the next strategic decision underwritable.
TSCIP helps clinical-stage oncology companies when promising science has not yet translated into a clear partnering, development or capital decision. We identify the strategic uncertainty preventing action, validate it in the field, and shape the next value-changing path.
The gap TSCIP addresses
Good science does not automatically create a transaction.
Clinical programs often reach a point where the next experiment, the next financing and the next partnering conversation are treated as separate problems. They usually are not.
02 / DEVELOPMENT
The next study is larger than the question.
More data is not always more valuable. The critical issue is which evidence would materially change a strategic decision.
03 / CAPITAL
Capital is discussed before the value inflection is clear.
A financeable plan becomes stronger when the use of capital is tied to a defined uncertainty and a credible decision on the other side.
How we work
Development strategy built around the next decision.
TSCIP does not publish its internal model. The public process is intentionally simple: clarify, validate, shape and execute.
01
Clarify
Frame the exact strategic uncertainty preventing a partner, investor or internal team from moving forward.
02
Validate
Test the thesis with relevant external decision-makers and distinguish genuine evidence requirements from polite interest.
03
Shape
Translate validated feedback into a bounded, practical path designed to create a meaningful value inflection.
04
Execute
Support re-engagement, diligence framing and transaction discussions around the newly clarified decision.
Protected intelligence layer
TSCIP™ stays behind the interface.
TSCIP uses a proprietary decision architecture to support asset assessment, strategic prioritization and field execution. Public materials describe the output—not the recipe.
What remains private
Internal scoring rules, datasets, partner-selection logic, asset-ranking methods, decision thresholds and evidence-design architecture are not disclosed on the public site.
Three strategic rails
Partnering, evidence and capital should solve the same problem.
TSCIP connects three decisions that are often managed separately. The objective is to align the next development step, the strategic counterparty and the capital required to reach a specific value inflection.
01
Strategic Partnering
Identify the strategic uncertainty preventing a credible counterparty from acting, validate that issue through field dialogue, and sharpen the re-engagement thesis.
02
Evidence & Development Strategy
Define the bounded evidence package most likely to change a partner, board or capital-allocation decision—rather than defaulting to a larger study simply to generate more data.
03
Strategic & Structured Capital
Frame the capital requirement around the value inflection it is intended to purchase, then evaluate structures that may preserve strategic optionality and reduce unnecessary dilution.
Capital architecture
Finance the decision—not just the runway.
TSCIP can help management model the amount, timing and form of capital needed to reach a defined evidence milestone, compare strategic and structured alternatives, and prepare the decision rationale for direct company-led discussions.
Strategic investment
Co-development funding
Regional licensing
Option structures
Royalty monetization
Synthetic royalties
Asset-level financing
Structured debt
Illustrative pharma venture organizations
Pfizer Ventures · Sanofi Ventures · Johnson & Johnson Innovation – JJDC
Illustrative royalty / structured-capital organizations
Royalty Pharma · HealthCare Royalty (HCRx) · DRI Healthcare
Independent market examples only.
The organizations named above are examples of publicly active participants in the life-sciences
capital ecosystem. TSCIP and Nectid have no affiliation, endorsement, partnership, agency,
referral arrangement or other relationship with these organizations unless separately and
expressly disclosed in writing. Their inclusion does not indicate interest in any TSCIP asset
or likelihood of financing a transaction.
Role boundary: TSCIP and Nectid provide strategic advisory, business-development
and decision-support services. They are not broker-dealers, placement agents, investment banks
or securities intermediaries; they do not offer or sell securities, handle investor funds, or
receive transaction-based compensation for securities placements. TSCIP may help management
evaluate capital structures, define financing requirements and prepare a company-led outreach
strategy. Any securities placement activity should be conducted directly by the company or
through an appropriately registered intermediary.
Who TSCIP serves
One decision framework. Different sides of the table.
The platform is designed for clinical-stage assets where the remaining uncertainty is strategic enough to affect development, partnering or capital allocation.
For asset owners
Convert ambiguous external interest into a sharper decision, a prioritized evidence question and a more executable path to re-engagement.
- Partner-ready asset thesis
- External decision validation
- Prioritized evidence question
- Value-inflection action plan
- Capital-architecture assessment
- BD and transaction support
For pharma & development-capital partners
Review opportunities through the uncertainty that matters, not just the narrative the seller wants to present.
- Curated clinical-stage opportunities
- Clear articulation of residual uncertainty
- Decision-focused diligence framing
- Direct access to asset owners when appropriate
- Defined use-of-capital logic around a value inflection
Anonymous worked example
When partner interest is real—but not actionable.
A clinical-stage oncology program had encouraging human data and repeated strategic interest, yet conversations were not converting into a committed transaction.
Identity intentionally withheld01
Starting point
The program had enough clinical signal to attract serious attention, but "more data" was being discussed as a generic solution rather than as a precise decision requirement.
02
Field signal
Direct external dialogue converged on a recurring concern: the incremental contribution of the asset inside a combination had not been isolated clearly enough for counterparties to underwrite the next step.
03
Reframed development question
Instead of expanding the program broadly, the next evidence package was reframed around one bounded question that could materially change the partner decision.
04
Strategic result
The asset moved from an open-ended "generate more data" problem to a clearer value-inflection plan that could be discussed with both strategic counterparties and sources of development capital.
Anonymous worked example based on a TSCIP engagement. Sponsor, asset, indication,
mechanism, counterparties, institutions and non-public program details have been deliberately omitted.
Transaction experience
Built from more than advisory theory.
TSCIP builds on Nectid's prior experience creating therapeutic IP, positioning it for a strategic counterparty and carrying that work into a completed transaction.
Nectid-originated therapeutic IP → Grünenthal GmbH
A patent portfolio originating from Nectid was later acquired by Grünenthal. The historical precedent matters because it reflects the same discipline behind TSCIP today: differentiated thesis, defensibility, strategic fit and transaction execution.
Public transaction
2011
About TSCIP
Decision intelligence for oncology assets.
TSCIP
A proprietary platform developed and operated by Nectid
TSCIP brings together biotechnology business development, therapeutic strategy, field validation and technology-enabled decision support.
Engagements are intentionally selective and built around clinical assets where a specific strategic uncertainty can be tested in the market and translated into an actionable development, partnering or capital decision.
TSCIP is a proprietary platform developed and operated by Nectid.
Contact
Have an asset caught between clinical promise and a transaction?
Start with the decision you are trying to unlock. Initial conversations should stay non-confidential until both sides agree otherwise.